Perspectives and opportunities for nanomedicine in the management of atherosclerosis

[1]  V. Taviani,et al.  Effect of low-and high-dose atorvastatin on carotid artery distensibility using carotid magnetic resonance imaging -a post-hoc sub group analysis of ATHEROMA (Atorvastatin Therapy: Effects On Reduction Of Macrophage Activity) Study. , 2013, Journal of atherosclerosis and thrombosis.

[2]  D. Absher,et al.  Design and Challenges , 2012 .

[3]  Tal Dvir,et al.  Nanotechnological strategies for engineering complex tissues. , 2020, Nature nanotechnology.

[4]  Ralph Weissleder,et al.  Dextran-coated iron oxide nanoparticles: a versatile platform for targeted molecular imaging, molecular diagnostics, and therapy. , 2011, Accounts of chemical research.

[5]  S. Wickline,et al.  Thrombin‐inhibiting perfluorocarbon nanoparticles provide a novel strategy for the treatment and magnetic resonance imaging of acute thrombosis , 2011, Journal of thrombosis and haemostasis : JTH.

[6]  Mario J. Garcia,et al.  Report of the National Heart, Lung, and Blood Institute working group on the translation of cardiovascular molecular imaging. , 2011, Circulation.

[7]  G. De Luca,et al.  Immunosuppressive therapy with oral prednisone to prevent restenosis after PCI. A multicenter randomized trial. , 2011, The American journal of medicine.

[8]  P. Joshi,et al.  Coronary atherosclerosis imaging by coronary CT angiography: current status, correlation with intravascular interrogation and meta-analysis. , 2011, JACC. Cardiovascular imaging.

[9]  Elliot L Chaikof,et al.  Microfabrication and nanotechnology in stent design. , 2011, Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology.

[10]  R. Taub,et al.  Anti-inflammatory therapeutics for the treatment of atherosclerosis , 2011, Nature Reviews Drug Discovery.

[11]  D. Rader,et al.  Novel HDL-directed pharmacotherapeutic strategies , 2011, Nature Reviews Cardiology.

[12]  P. Libby,et al.  Progress and challenges in translating the biology of atherosclerosis , 2011, Nature.

[13]  S. Reddy,et al.  HDL and cardiovascular disease: atherogenic and atheroprotective mechanisms , 2011, Nature Reviews Cardiology.

[14]  R. Weissleder,et al.  Detection of Macrophages in Aortic Aneurysms by Nanoparticle Positron Emission Tomography–Computed Tomography , 2011, Arteriosclerosis, thrombosis, and vascular biology.

[15]  A. Pandit,et al.  Standardization of models and methods used to assess nanoparticles in cardiovascular applications. , 2011, Small.

[16]  Jun Fang,et al.  The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. , 2011, Advanced drug delivery reviews.

[17]  Masataka Nakano,et al.  The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents. , 2011, Journal of the American College of Cardiology.

[18]  Honglin Jin,et al.  Efficient cytosolic delivery of siRNA using HDL-mimicking nanoparticles. , 2011, Small.

[19]  Matthias Nahrendorf,et al.  Molecular Imaging of Coronary Atherosclerosis and Myocardial Infarction: Considerations for the Bench and Perspectives for the Clinic , 2011, Circulation research.

[20]  Chad A Mirkin,et al.  Biomimetic high density lipoprotein nanoparticles for nucleic acid delivery. , 2011, Nano letters.

[21]  D. Mooney,et al.  Targeted delivery of nanoparticles to ischemic muscle for imaging and therapeutic angiogenesis. , 2011, Nano letters.

[22]  I. Y. Chen,et al.  Cardiovascular molecular imaging: focus on clinical translation. , 2011, Circulation.

[23]  D. Mozaffarian,et al.  Heart disease and stroke statistics--2011 update: a report from the American Heart Association. , 2011, Circulation.

[24]  Young Seok Cho,et al.  Targeted iron oxide particles for in vivo magnetic resonance detection of atherosclerotic lesions with antibodies directed to oxidation-specific epitopes. , 2011, Journal of the American College of Cardiology.

[25]  K. Vickers,et al.  MicroRNAs are Transported in Plasma and Delivered to Recipient Cells by High-Density Lipoproteins , 2011, Nature Cell Biology.

[26]  Robert L Wilensky,et al.  Cholesterol efflux capacity, high-density lipoprotein function, and atherosclerosis. , 2011, The New England journal of medicine.

[27]  Zahi A Fayad,et al.  The biological properties of iron oxide core high-density lipoprotein in experimental atherosclerosis. , 2011, Biomaterials.

[28]  R. Krams,et al.  Contrast enhancement by differently sized paramagnetic MRI contrast agents in mice with two phenotypes of atherosclerotic plaque. , 2011, Contrast media & molecular imaging.

[29]  A. Rehemtulla,et al.  Molecular Imaging , 2009, Methods in Molecular Biology.

[30]  S. Chien,et al.  Effects of disturbed flow on vascular endothelium: pathophysiological basis and clinical perspectives. , 2011, Physiological reviews.

[31]  K. Nguyen,et al.  Autonomic Denervation With Magnetic Nanoparticles , 2010, Circulation.

[32]  Betty Y. S. Kim,et al.  Current concepts: Nanomedicine , 2010 .

[33]  J. Schlomka,et al.  Computed tomography in color: NanoK-enhanced spectral CT molecular imaging. , 2010, Angewandte Chemie.

[34]  Z. Fayad,et al.  Quantum dot and Cy5.5 labeled nanoparticles to investigate lipoprotein biointeractions via Förster resonance energy transfer. , 2010, Nano letters.

[35]  V. Fuster,et al.  Multimodal clinical imaging to longitudinally assess a nanomedical anti-inflammatory treatment in experimental atherosclerosis. , 2010, Molecular pharmaceutics.

[36]  Gary S Mintz,et al.  In-stent restenosis in the drug-eluting stent era. , 2010, Journal of the American College of Cardiology.

[37]  R. Collins,et al.  Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trial , 2010, The Lancet.

[38]  Hak Soo Choi,et al.  Nanoparticles for Biomedical Imaging: Fundamentals of Clinical Translation , 2010, Molecular imaging.

[39]  Z. Fayad,et al.  Annexin A5-functionalized bimodal nanoparticles for MRI and fluorescence imaging of atherosclerotic plaques. , 2010, Bioconjugate chemistry.

[40]  Jun-ichiro Jo,et al.  An ultrasound-responsive nano delivery system of tissue-type plasminogen activator for thrombolytic therapy. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[41]  E. Falk,et al.  Atherosclerotic lesions in mouse and man: is it the same disease? , 2010, Current opinion in lipidology.

[42]  S. Caruthers,et al.  Rationale for a nanomedicine approach to thrombolytic therapy. , 2010, Stroke.

[43]  Ralph Weissleder,et al.  A light-activated theranostic nanoagent for targeted macrophage ablation in inflammatory atherosclerosis. , 2010, Small.

[44]  Axel Thran,et al.  Note: This Copy Is for Your Personal, Non-commercial Use Only. to Order Presentation-ready Copies for Distribution to Your Colleagues or Clients, Contact Us at Www.rsna.org/rsnarights. Atherosclerotic Plaque Composition: Analysis with Multicolor Ct and Targeted Gold Nanoparticles 1 Materials and Met , 2022 .

[45]  P. Conti,et al.  Target-specific delivery of peptide-based probes for PET imaging. , 2010, Advanced drug delivery reviews.

[46]  U. Schubert,et al.  Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. , 2010, Angewandte Chemie.

[47]  Jay Landers,et al.  Entering the Mainstream , 2010 .

[48]  Joseph M. DeSimone,et al.  Strategies in the design of nanoparticles for therapeutic applications , 2010, Nature Reviews Drug Discovery.

[49]  John M Tarbell,et al.  Shear stress and the endothelial transport barrier. , 2010, Cardiovascular research.

[50]  S. Caruthers,et al.  Angiogenesis imaging with vascular-constrained particles: the why and how , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[51]  V. Fuster,et al.  The BioImage Study: novel approaches to risk assessment in the primary prevention of atherosclerotic cardiovascular disease--study design and objectives. , 2010, American heart journal.

[52]  V. Fuster,et al.  Imaging atherosclerotic plaque inflammation by fluorodeoxyglucose with positron emission tomography: ready for prime time? , 2010, Journal of the American College of Cardiology.

[53]  P. Newburger,et al.  Local arterial nanoparticle delivery of siRNA for NOX2 knockdown to prevent restenosis in an atherosclerotic rat model , 2010, Gene Therapy.

[54]  P. Choyke,et al.  New strategies for fluorescent probe design in medical diagnostic imaging. , 2010, Chemical reviews.

[55]  Angelique Louie,et al.  Multimodality imaging probes: design and challenges. , 2010, Chemical reviews.

[56]  Enzo Terreno,et al.  Challenges for molecular magnetic resonance imaging. , 2010, Chemical reviews.

[57]  Mansoor Amiji,et al.  Targeting stents with local delivery of paclitaxel-loaded magnetic nanoparticles using uniform fields , 2010, Proceedings of the National Academy of Sciences.

[58]  Chun Yuan,et al.  MRI of carotid atherosclerosis: clinical implications and future directions , 2010, Nature Reviews Cardiology.

[59]  M. Reiser,et al.  In Vivo Imaging of Macrophage Activity in the Coronary Arteries Using 68Ga-DOTATATE PET/CT: Correlation with Coronary Calcium Burden and Risk Factors , 2010, Journal of Nuclear Medicine.

[60]  Zahi A Fayad,et al.  High-density lipoprotein-based contrast agents for multimodal imaging of atherosclerosis. , 2010, Arteriosclerosis, thrombosis, and vascular biology.

[61]  K. G. Rajeev,et al.  Rational design of cationic lipids for siRNA delivery , 2010, Nature Biotechnology.

[62]  S. Reddy,et al.  Structure and function of HDL mimetics. , 2010, Arteriosclerosis, thrombosis, and vascular biology.

[63]  Robert Langer,et al.  Spatiotemporal controlled delivery of nanoparticles to injured vasculature , 2010, Proceedings of the National Academy of Sciences.

[64]  F. Geissmann,et al.  Monocytes in atherosclerosis: subsets and functions , 2010, Nature Reviews Cardiology.

[65]  Kathryn A. Whitehead,et al.  Lipid-like materials for low-dose, in vivo gene silencing , 2010, Proceedings of the National Academy of Sciences.

[66]  H. Caron,et al.  Different anthracycline derivates for reducing cardiotoxicity in cancer patients. , 2010, The Cochrane database of systematic reviews.

[67]  I. Tabas.  Macrophage death and defective inflammation resolution in atherosclerosis , 2010, Nature Reviews Immunology.

[68]  Paul M Ridker,et al.  Inflammation in atherosclerosis: from pathophysiology to practice. , 2009, Journal of the American College of Cardiology.

[69]  L. Pendyala,et al.  The first-generation drug-eluting stents and coronary endothelial dysfunction. , 2009, JACC. Cardiovascular interventions.

[70]  Ralph Weissleder,et al.  Hybrid In Vivo FMT-CT Imaging of Protease Activity in Atherosclerosis With Customized Nanosensors , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[71]  J. Dubochet,et al.  Extracellular matrix binding mixed micelles for drug delivery applications. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[72]  T. Xia,et al.  Understanding biophysicochemical interactions at the nano-bio interface. , 2009, Nature materials.

[73]  Jonathan R. Lindner,et al.  Molecular imaging of cardiovascular disease with contrast-enhanced ultrasonography , 2009, Nature Reviews Cardiology.

[74]  Ralph Weissleder,et al.  Optical and Multimodality Molecular Imaging: Insights Into Atherosclerosis , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[75]  V. Fuster,et al.  Promoting mechanisms of vascular health: circulating progenitor cells, angiogenesis, and reverse cholesterol transport. , 2009, Journal of the American College of Cardiology.

[76]  Erkki Ruoslahti,et al.  Targeting atherosclerosis by using modular, multifunctional micelles , 2009, Proceedings of the National Academy of Sciences.

[77]  Konstantin Sokolov,et al.  Plasmonic intravascular photoacoustic imaging for detection of macrophages in atherosclerotic plaques. , 2009, Nano letters.

[78]  Z. Fayad,et al.  Iron oxide magnetic resonance imaging for atherosclerosis therapeutic evaluation: still "rusty?". , 2009, Journal of the American College of Cardiology.

[79]  Martin J Graves,et al.  The ATHEROMA (Atorvastatin Therapy: Effects on Reduction of Macrophage Activity) Study. Evaluation using ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging in carotid disease. , 2009, Journal of the American College of Cardiology.

[80]  Z. Fayad,et al.  Comparison of synthetic high density lipoprotein (HDL) contrast agents for MR imaging of atherosclerosis. , 2009, Bioconjugate chemistry.

[81]  Klaas Nicolay,et al.  Nanoparticulate assemblies of amphiphiles and diagnostically active materials for multimodality imaging. , 2009, Accounts of chemical research.

[82]  H. Kruth,et al.  Fluorescent pegylated nanoparticles demonstrate fluid-phase pinocytosis by macrophages in mouse atherosclerotic lesions. , 2009, The Journal of clinical investigation.

[83]  Young Keun Kim,et al.  A highly sensitive and selective diagnostic assay based on virus nanoparticles. , 2009, Nature nanotechnology.

[84]  Formulation of nanoparticle-eluting stents by a cationic electrodeposition coating technology: efficient nano-drug delivery via bioabsorbable polymeric nanoparticle-eluting stents in porcine coronary arteries. , 2009, JACC. Cardiovascular interventions.

[85]  高濱 博幸.  Prolonged Targeting of Ischemic/reperfused Myocardium by Liposomal Adenosine Augments Cardioprotection in Rats , 2009 .

[86]  Gordon H Guyatt,et al.  Association between change in high density lipoprotein cholesterol and cardiovascular disease morbidity and mortality: systematic review and meta-regression analysis , 2009, BMJ : British Medical Journal.

[87]  C. Mirkin,et al.  Templated spherical high density lipoprotein nanoparticles. , 2009, Journal of the American Chemical Society.

[88]  Robert Langer,et al.  Impact of nanotechnology on drug delivery. , 2009, ACS nano.

[89]  Monica Shokeen,et al.  Biodegradable dendritic positron-emitting nanoprobes for the noninvasive imaging of angiogenesis , 2009, Proceedings of the National Academy of Sciences.

[90]  Samir Mitragotri,et al.  Physical approaches to biomaterial design. , 2009, Nature materials.

[91]  N. Wong,et al.  Molecular imaging of matrix metalloproteinase in atherosclerotic lesions: resolution with dietary modification and statin therapy. , 2008, Journal of the American College of Cardiology.

[92]  K Ann McKibbon,et al.  Current status and future prospects. , 2008, Health information and libraries journal.

[93]  R. Virmani,et al.  Site-Specific Targeting of Nanoparticle Prednisolone Reduces In-Stent Restenosis in a Rabbit Model of Established Atheroma , 2008, Arteriosclerosis, Thrombosis and Vascular Biology.

[94]  Claudia Calcagno,et al.  Nanocrystal core high-density lipoproteins: a multimodality contrast agent platform. , 2008, Nano letters.

[95]  T. Alan Hatton,et al.  Nanoparticles: Synthesis, Stabilization, Passivation, and Functionalization , 2008 .

[96]  Shelton D Caruthers,et al.  Antiangiogenic synergism of integrin-targeted fumagillin nanoparticles and atorvastatin in atherosclerosis. , 2008, JACC. Cardiovascular imaging.

[97]  Mark E. Davis,et al.  Nanoparticle therapeutics: an emerging treatment modality for cancer , 2008, Nature Reviews Drug Discovery.

[98]  Eric Pridgen,et al.  Factors Affecting the Clearance and Biodistribution of Polymeric Nanoparticles , 2008, Molecular pharmaceutics.

[99]  Rolf Schubert,et al.  In Vivo Monitoring of Inflammation After Cardiac and Cerebral Ischemia by Fluorine Magnetic Resonance Imaging , 2008, Circulation.

[100]  P. Allavena,et al.  Cancer-related inflammation , 2008, Nature.

[101]  H. Herrmann.  Bare-Metal and Drug-Eluting Stents: What’s the Bottom Line? , 2008 .

[102]  A. Lindsay,et al.  Form to function: current and future roles for atherosclerosis imaging in drug development , 2008, Nature Reviews Drug Discovery.

[103]  Shelton D Caruthers,et al.  Intramural Delivery of Rapamycin With &agr;v&bgr;3-Targeted Paramagnetic Nanoparticles Inhibits Stenosis After Balloon Injury , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[104]  L. Zhang,et al.  Nanoparticles in Medicine: Therapeutic Applications and Developments , 2008, Clinical pharmacology and therapeutics.

[105]  Gemma Vilahur,et al.  Rapid change in plaque size, composition, and molecular footprint after recombinant apolipoprotein A-I Milano (ETC-216) administration: magnetic resonance imaging study in an experimental model of atherosclerosis. , 2008, Journal of the American College of Cardiology.

[106]  Warren C W Chan,et al.  Nanoparticle-mediated cellular response is size-dependent. , 2008, Nature nanotechnology.

[107]  Zahi A. Fayad,et al.  Imaging of atherosclerotic cardiovascular disease , 2008, Nature.

[108]  Daniel J. Rader,et al.  Translating molecular discoveries into new therapies for atherosclerosis , 2008, Nature.

[109]  Ralph Weissleder,et al.  Nanoparticle PET-CT Imaging of Macrophages in Inflammatory Atherosclerosis , 2008, Circulation.

[110]  Gary Friedman,et al.  High field gradient targeting of magnetic nanoparticle-loaded endothelial cells to the surfaces of steel stents , 2008, Proceedings of the National Academy of Sciences.

[111]  D. Rader,et al.  patient-oriented and epidemiological research Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients , 2008 .

[112]  J. Karp,et al.  Nanocarriers as an Emerging Platform for Cancer Therapy , 2022 .

[113]  J. Borén,et al.  Ira Tabas , Kevin Jon Williams and Jan Borén and Therapeutic Implications Subendothelial Lipoprotein Retention as the Initiating Process in Atherosclerosis : Update , 2007 .

[114]  M. Bawendi,et al.  Renal clearance of quantum dots , 2007, Nature Biotechnology.

[115]  Wolfgang A. Weber,et al.  Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging , 2007, Proceedings of the National Academy of Sciences.

[116]  R. Virmani,et al.  Antiangiogenic therapy for normalization of atherosclerotic plaque vasculature: a potential strategy for plaque stabilization , 2007, Nature Clinical Practice Cardiovascular Medicine.

[117]  M. Dobrovolskaia,et al.  Immunological properties of engineered nanomaterials , 2007, Nature Nanotechnology.

[118]  Klaas Nicolay,et al.  Magnetic and fluorescent nanoparticles for multimodality imaging. , 2007, Nanomedicine.

[119]  Simon Capewell,et al.  Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. , 2007, The New England journal of medicine.

[120]  R. Virmani,et al.  Elimination of neoangiogenesis for plaque stabilization: is there a role for local drug therapy? , 2007, Journal of the American College of Cardiology.

[121]  Zahi A Fayad,et al.  Noninvasive detection of macrophages using a nanoparticulate contrast agent for computed tomography , 2007, Nature Medicine.

[122]  Seppo Ylä-Herttuala,et al.  Vascular endothelial growth factors: biology and current status of clinical applications in cardiovascular medicine. , 2007, Journal of the American College of Cardiology.

[123]  Michael Joner,et al.  Drug-Eluting Stent and Coronary Thrombosis: Biological Mechanisms and Clinical Implications , 2007, Circulation.

[124]  Zahi A Fayad,et al.  Detecting and assessing macrophages in vivo to evaluate atherosclerosis noninvasively using molecular MRI , 2007, Proceedings of the National Academy of Sciences.

[125]  A. Alavi,et al.  Opportunities and Challenges , 1998, In Vitro Diagnostic Industry in China.

[126]  Ralph Weissleder,et al.  Noninvasive Vascular Cell Adhesion Molecule-1 Imaging Identifies Inflammatory Activation of Cells in Atherosclerosis , 2006, Circulation.

[127]  Volker Wagner,et al.  The emerging nanomedicine landscape , 2006, Nature Biotechnology.

[128]  Samuel A. Wickline,et al.  Endothelial &agr;&ngr;&bgr;3 Integrin–Targeted Fumagillin Nanoparticles Inhibit Angiogenesis in Atherosclerosis , 2006 .

[129]  Christopher P Cannon,et al.  Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. , 2006, Journal of the American College of Cardiology.

[130]  V. Fuster,et al.  Neovascularization in human atherosclerosis. , 2006, Current molecular medicine.

[131]  Peter Libby,et al.  The immune response in atherosclerosis: a double-edged sword , 2006, Nature Reviews Immunology.

[132]  U. Nielsen,et al.  Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. , 2006, Cancer research.

[133]  Matthias John,et al.  RNAi-mediated gene silencing in non-human primates , 2006, Nature.

[134]  E. Tuzcu,et al.  Relationship between atheroma regression and change in lumen size after infusion of apolipoprotein A-I Milano. , 2006, Journal of the American College of Cardiology.

[135]  Jan Grimm,et al.  An X-ray computed tomography imaging agent based on long-circulating bismuth sulphide nanoparticles , 2006, Nature materials.

[136]  Nicholas A Peppas,et al.  Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. , 2006, International journal of pharmaceutics.

[137]  V. Torchilin.  Multifunctional nanocarriers. , 2006, Advanced drug delivery reviews.

[138]  Hui Li,et al.  Rerouting lipoprotein nanoparticles to selected alternate receptors for the targeted delivery of cancer diagnostic and therapeutic agents. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[139]  Peter Libby,et al.  The forgotten majority: unfinished business in cardiovascular risk reduction. , 2005, Journal of the American College of Cardiology.

[140]  W. Aird,et al.  Forkhead Transcription Factors Inhibit Vascular Smooth Muscle Cell Proliferation and Neointimal Hyperplasia*[boxs] , 2005, Journal of Biological Chemistry.

[141]  V. Fuster,et al.  Effects of aggressive versus conventional lipid-lowering therapy by simvastatin on human atherosclerotic lesions: a prospective, randomized, double-blind trial with high-resolution magnetic resonance imaging. , 2005, Journal of the American College of Cardiology.

[142]  A. Sanabria,et al.  Randomized controlled trial. , 2005, World journal of surgery.

[143]  Elena Bonanno,et al.  Diffuse and active inflammation occurs in both vulnerable and stable plaques of the entire coronary tree: a histopathologic study of patients dying of acute myocardial infarction. , 2005, Journal of the American College of Cardiology.

[144]  M. Ferrari.  Cancer nanotechnology: opportunities and challenges , 2005, Nature Reviews Cancer.

[145]  A. C. Hunter,et al.  Nanomedicine: current status and future prospects , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[146]  V. Torchilin.  Recent advances with liposomes as pharmaceutical carriers , 2005, Nature Reviews Drug Discovery.

[147]  S. Kaul,et al.  Rapid reversal of endothelial dysfunction in hypercholesterolemic apolipoprotein E-null mice by recombinant apolipoprotein A-I(Milano)-phospholipid complex. , 2004, Journal of the American College of Cardiology.

[148]  V. Fuster,et al.  Lipid-Rich Atherosclerotic Plaques Detected by Gadofluorine-Enhanced In Vivo Magnetic Resonance Imaging , 2004, Circulation.

[149]  M. Daemen,et al.  Noninvasive detection of plaque instability with use of radiolabeled annexin A5 in patients with carotid-artery atherosclerosis. , 2004, The New England journal of medicine.

[150]  P. Cullis,et al.  Drug Delivery Systems: Entering the Mainstream , 2004, Science.

[151]  E. Edelman,et al.  Liposomal Alendronate Inhibits Systemic Innate Immunity and Reduces In-Stent Neointimal Hyperplasia in Rabbits , 2003, Circulation.

[152]  Paul Schoenhagen,et al.  Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. , 2003, JAMA.

[153]  Samuel A. Wickline,et al.  Molecular Imaging of Angiogenesis in Early-Stage Atherosclerosis With &agr;v&bgr;3-Integrin–Targeted Nanoparticles , 2003 .

[154]  E. Boerwinkle,et al.  From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: Part I. , 2003, Circulation.

[155]  J. Hartikainen,et al.  Safety and Feasibility of Catheter-Based Local Intracoronary Vascular Endothelial Growth Factor Gene Transfer in the Prevention of Postangioplasty and In-Stent Restenosis and in the Treatment of Chronic Myocardial Ischemia: Phase II Results of the Kuopio Angiogenesis Trial (KAT) , 2003, Circulation.

[156]  S. Kaul,et al.  Intramural Delivery of Recombinant Apolipoprotein A-IMilano/Phospholipid Complex (ETC-216) Inhibits In-Stent Stenosis in Porcine Coronary Arteries , 2003, Circulation.

[157]  M. E. Kooi,et al.  Accumulation of Ultrasmall Superparamagnetic Particles of Iron Oxide in Human Atherosclerotic Plaques Can Be Detected by In Vivo Magnetic Resonance Imaging , 2003, Circulation.

[158]  Keiji Oi,et al.  Application of Nanoparticle Technology for the Prevention of Restenosis After Balloon Injury in Rats , 2003, Circulation research.

[159]  David Zurakowski,et al.  Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[160]  P. Libby.  Inflammation in atherosclerosis , 2002, Nature.

[161]  Kerry K. Karukstis,et al.  Targeted Antiproliferative Drug Delivery to Vascular Smooth Muscle Cells With a Magnetic Resonance Imaging Nanoparticle Contrast Agent: Implications for Rational Therapy of Restenosis , 2002, Circulation.

[162]  R. Virmani,et al.  Sustained Reduction of In-Stent Neointimal Growth With the Use of a Novel Systemic Nanoparticle Paclitaxel , 2002, Circulation.

[163]  I. Fishbein,et al.  Macrophage Depletion by Clodronate-Containing Liposomes Reduces Neointimal Formation After Balloon Injury in Rats and Rabbits , 2002, Circulation.

[164]  C. Di Mario,et al.  Recombinant Apolipoprotein A-IMilano Infusion Into Rabbit Carotid Artery Rapidly Removes Lipid From Fatty Streaks , 2002, Circulation research.

[165]  S A Wickline,et al.  Novel MRI Contrast Agent for Molecular Imaging of Fibrin: Implications for Detecting Vulnerable Plaques , 2001, Circulation.

[166]  S. Kaul,et al.  High-Dose Recombinant Apolipoprotein A-IMilano Mobilizes Tissue Cholesterol and Rapidly Reduces Plaque Lipid and Macrophage Content in Apolipoprotein E-Deficient Mice: Potential Implications for Acute Plaque Stabilization , 2001, Circulation.

[167]  T. V. van Berkel,et al.  Recombinant lipoproteins: lipoprotein-like lipid particles for drug targeting. , 2001, Advanced drug delivery reviews.

[168]  J. Fallon,et al.  Dexamethasone inhibits macrophage accumulation after balloon arterial injury in cholesterol fed rabbits. , 2001, Atherosclerosis.

[169]  M. Dake,et al.  Vascular endothelial growth factor enhances atherosclerotic plaque progression , 2001, Nature Medicine.

[170]  J. Debatin,et al.  Magnetic Resonance Imaging of Atherosclerotic Plaque With Ultrasmall Superparamagnetic Particles of Iron Oxide in Hyperlipidemic Rabbits , 2001, Circulation.

[171]  A. M. Lefer,et al.  Rapid restoration of normal endothelial functions in genetically hyperlipidemic mice by a synthetic mediator of reverse lipid transport. , 2000, Arteriosclerosis, thrombosis, and vascular biology.

[172]  A. D. Watson,et al.  Metal-Based X-ray Contrast Media. , 1999, Chemical reviews.

[173]  M A Konerding,et al.  Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. , 1999, Circulation.

[174]  P Bailey,et al.  Double Edged Sword , 2002 .

[175]  V. Torchilin,et al.  CT visualization of blood pool in rats by using long-circulating, iodine-containing micelles. , 1999, Academic radiology.

[176]  W. Rodrigueza,et al.  Structural and metabolic consequences of liposome-lipoprotein interactions. , 1998, Advanced Drug Delivery Reviews.

[177]  S. Kaul,et al.  Effects of recombinant apolipoprotein A-I(Milano) on aortic atherosclerosis in apolipoprotein E-deficient mice. , 1998, Circulation.

[178]  M. Hope,et al.  Cholesterol mobilization and regression of atheroma in cholesterol-fed rabbits induced by large unilamellar vesicles. , 1998, Biochimica et biophysica acta.

[179]  J. G. Miller,et al.  A novel site-targeted ultrasonic contrast agent with broad biomedical application. , 1996, Circulation.

[180]  V. Fuster,et al.  Coronary plaque disruption. , 1995, Circulation.

[181]  T. Allen.  Long-circulating (sterically stabilized) liposomes for targeted drug delivery. , 1994, Trends in pharmacological sciences.

[182]  V. Torchilin,et al.  Targeted accumulation of polyethylene glycol‐coated immunoliposomes in infarcted rabbit myocardium , 1992, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[183]  H. Hodis,et al.  Relationship of arterial wall uptake of radiolabeled liposomes to the presence of monocyte/macrophage cells in the hypertensive and atherosclerotic arterial wall. , 1991, Atherosclerosis.

[184]  Kazuo Maruyama,et al.  Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes , 1990, FEBS letters.

[185]  V. Fuster,et al.  Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. , 1990, The Journal of clinical investigation.

[186]  D. Gordon,et al.  High-density lipoprotein--the clinical implications of recent studies. , 1989, The New England journal of medicine.

[187]  V. Fuster,et al.  High density lipoprotein plasma fractions inhibit aortic fatty streaks in cholesterol-fed rabbits. , 1989, Laboratory investigation; a journal of technical methods and pathology.

[188]  H. Maeda,et al.  A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.

[189]  S. Moore,et al.  Pathogenesis of atherosclerosis. , 1985, Metabolism: clinical and experimental.

[190]  B. Zaret,et al.  Liposome accumulation in regions of experimental myocardial infarction. , 1977, Science.

[191]  G. Miller,et al.  PLASMA-HIGH-DENSITY-LIPOPROTEIN CONCENTRATION AND DEVELOPMENT OF ISCHÆMIC HEART-DISEASE , 1975, The Lancet.

[192]  I. M. Neiman,et al.  [Inflammation and cancer]. , 1974, Patologicheskaia fiziologiia i eksperimental'naia terapiia.

[193]  H. Selznick,et al.  The New Statistics , 2014, Psychological science.